Biotechnology company developing genome editing technologies to treat genetically defined diseases.
Editas Medicine, Inc. is a pioneering clinical-stage genome editing company headquartered in Cambridge, Massachusetts, dedicated to developing revolutionary genomic medicines for a variety of severe diseases. Established in 2013 and originally named Gengine, Inc., the company rebranded as Editas Medicine, Inc. in November 2013 to reflect its commitment to advancing medical science through CRISPR-based gene editing technologies.
At the forefront of its innovation is a proprietary gene editing platform leveraging CRISPR technology. Editas Medicine is actively advancing several transformative programs, including EDIT-101, currently in Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a genetic disorder leading to childhood blindness. The company is also developing EDIT-102 for Usher Syndrome 2A, a form of retinitis pigmentosa associated with hearing loss, and EDIT-301 targeting sickle cell disease and transfusion-dependent beta-thalassemia.
In addition to its ocular and blood disorder therapies, Editas Medicine is pioneering gene-edited Natural Killer (NK) cell therapies for solid tumor cancers, alpha-beta T cell therapies for multiple cancers, and gamma delta T cell therapies for cancer treatment. The companys expansive research effforts include an early discovery program aimed at developing therapies for neurological diseases.
Editas Medicine collaborates extensively with industry leaders and research institutions to advance its groundbreaking therapies. Partnerships include a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer treatment, a strategic alliance with Allergan Pharmaceuticals International Limited focusing on gene editing medicines for ocular disorders, and research collaborations with Asklepios BioPharmaceutical, Inc. and AskBio in the pursuit of neurological disease therapies. With a steadfast commitment to innovation and patient care, Editas Medicine continues to push the boundaries of genomic medicine to address unmet medical needs worldwide.